Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Hits & Misses
    • Artificial Intelligence and Healthcare
    • Doctors & Hospitals
      • COVID-19 and Public Health
    • Policy & Legislation
      • Affordable Care Act
    • Health Economics & Costs
      • Cost of Healthcare
      • Drug Prices & Regulations
      • Health Reform
    • Health Insurance
      • Public Insurance
      • Medicare
    • Telemedicine
      • Medical Tourism
  • Goodman Institute
  • Contact
  • Search
The Goodman Institute Health Blog

Category: Health Economics & Costs

California is Going to Make its own Insulin

Posted on July 22, 2022 by John C. Goodman

Gov. Gavin Newsom says California will spend $100 million to develop low-cost insulin and build an in-state manufacturing facility.

+

How to Market an OTC Breathalyzer (that doesn’t work)

Posted on July 22, 2022 by Devon Herrick

Dallas billionaire Mark Cuban is in the news lately for his drug company startup, Cost Plus Drugs. Over the years Cuban was also on a show called Shark Tank, where would-be inventors and small business owners pitched their business ideas, competing for an investment.

While being interviewed for the “Full Send” podcast Mr. Cuban revealed his “worst” investment that he made on Shark Tank. An entrepreneur named Charles Yim appeared on the show to demonstrate his Breathometer, a smartphone breathalyzer app he claimed could test blood alcohol levels accurately.

+

Friday Links

Posted on July 22, 2022July 25, 2022 by John C. Goodman
  • AMA encourages doctors to learn health economics. They even have their own online course. Haven’t checked it out, but I suspect it is more sociology than economics.
  • Amazon wants to be your doctor.
  • Déjà vu: Monkeypox testing looks like the Covid testing fiasco all over again.
  • “probably half of all Covid infections have happened this calendar year — and it’s only July.”
  • Insulin bill in the Senate looks like a done deal.
+

Medicare Unlikely to Negotiate Lower Drug Prices than PBMs

Posted on July 21, 2022 by Devon Herrick

Senate Democrats are looking to lower Medicare drug costs by allowing Medicare to negotiate the prices it pays for a limited number of drugs. The Medicare Modernization Act of 2003 expressly forbid the government from interfering with negotiations between private payers and drug makers. However, allowing Medicare to negotiate directly with drug makers has long been a goal of Democrats and the idea is popular with voters.

+
  • Previous
  • 1
  • …
  • 445
  • 446
  • 447
  • 448
  • 449
  • 450
  • 451
  • …
  • 474
  • Next

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 43 other subscribers

Popular Topics

©2026 The Goodman Institute Health Blog | Website by Lexicom